Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Recent Research
Kcnc3 is also named Kv3.3. The Kv3.3 voltage-dependent K+ channel belongs to a class of ion channels sometimes termed ‘high-threshold’ or ‘high voltage-activated’ channels. These are typical delayed rectifier channels that are activated only when the potential is greater than ~ 20mv. Therefore, they contribute very little to resting potassium conductance, but are activated during the rise of action potential. Kv3.3 channels also activate and deactivate response voltage changes very quickly. Therefore, these channels produce very fast repolarization of the action potential with little or no relative refractory period, enabling neurons that express these channels to excite the action potential sequence at high frequencies. In the case of maintaining depolarization, the Kv3.3 channel experienced slow and partial deactivation, with a time course of several hundred milliseconds. This inactivation occurs through the n-type inactivation mechanism, which is eliminated by the loss of cytoplasm at the n-end of the pathway. Inactivation can also be regulated by activating protein kinase C. There is evidence that the phosphorylation of two serine residues in the n terminal region of Kv3.3 can prevent inactivation in the N-terminal region.
Kv3.3 channels are expressed in neurons that fire at high rates, particularly in the cerebellum and brainstem. High levels are also found in inhibitory parvalbumin-containing cortical interneurons that typically are capable of firing at hundreds of hertz, as well as in GABA-ergic interneurons in other parts of the nervous system. Many such neurons also express the Kv3.1 channel, and the high voltage-activated channels in such neurons may be heteromeric channels containing both Kv3.3 and Kv3.1. The Kv3.3 is also strongly expressed in most auditory brainstem nuclei, where neurons may be fired at a frequency of up to 600-800 Hertz to process auditory information.
Kv3.3 and SCA13
Spinalcerebellar ataxia type 13 (SCA13) is an autosomal dominant inherited neurodegenerative disease characterized by cerebellar atrophy, especially the vermis, leading to a cerebellar syndrome with dysarthria and nystagmus. It is sometimes accompanied by pyramidal signs, epilepsy, auditory deficits, and mild intellectual disability. The disease is caused by missense mutations in the KCNC3 gene.
One study demonstrating a link between human mutations in KCNC3 and ataxia reporting two different channel mutations: R420H, which leads to adult onset ataxia, and F448L, which results in childhood onset ataxia with cognitive delay. The R420H mutation is located in the S4 transmembrane domain that represents the major voltage sensor in these channels (Figure 1). Another mutation (R423H) has also been found in the S4 domain, but, in contrast to R420H, this produces a severe early onset spinocerebellar ataxia. The early onset F448L mutation is located in the S5 transmembrane region of the protein, close to the pore of the channel (Figure 1).
Figure 1 The Kv3.3 channel
While the primary focus of the effects of Kv3.3 mutations has been on cerebellar function, it is evident that other neuronal circuits can be severely impacted. A clear example of this is found in the auditory system where Kv3.3 channels are found at high levels in brain-stem circuits underlying sound localization. Moreover, when co-expressed with wild type Kv3.3 channels, with which they would be expected to form hetero-tetramers, R420H and R423H have a dominant-negative effect, suppressing overall current amplitude. In contrast to loss-of-function mutations such as R420H and R423H, other disease-causing mutations, such as the early onset F448L mutation, result in fully functional Kv3.3 channels that make it to the plasma membrane.
The Kv3.3 channel in most SCA13 patients is likely to be a tetramer containing both wild type and mutant channels. One report showed that co-expressed the late onset R420H mutant with wild type Kv3.3 channels. Although R420H reduced overall current amplitude, the kinetic behavior of the heteromeric channels was identical to that of homomeric wild type Kv3.3 channels. In contrast, the voltage dependence of the current that results from heteromeric R423H/wild type channels was found to be shifted to negative potentials. In this respect, the R423H/wild type heteromeric channels resemble F448L mutant channels, which also cause the early onset disease. Moreover, in addition to the altered voltage dependence, the kinetic behavior of the R423H/wild type heteromers was also different from that of wild type Kv3.3 homomers.
Lessons from Kv3.3 knockout animals
Kv3.3 channels are expressed in both the somata and the dendrites of cerebellar Purkinje cells. Consistent with a role for Kv3.3 in shaping the firing patterns of these neurons, Purkinje cell action potentials are broader in Kv3.3−/− mice than in wild type animals .These electro-physiological changes can be rescued by re-introducing wild type Kv3.3 channels selectively into Purkinje cells of Kv3.3−/− animals, but this does not rescue the motor behaviors. The excitability of the distal dendrites, and the amplitude of cytoplasmic Ca2+ signals evoked by stimulation of the dendrites, is also increased in Purkinje cells of Kv3.3−/− knockout mice. A much more severe motor phenotype is observed when the Kv3.3 gene is deleted in combination with that for the closely related channel Kv3.1. Such double knockout animals have severe ataxia as well as other disorders of movement. They are constitutively hyperactive, appear unbalanced when moving, and undergo whole-body jerks every few seconds.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.